ELV Stock Spotlight: The CEO Keeps Buying

Most insider-buying signals we've looked at in this stock spotlight series involve a burst of activity that's already aged out of relevance by the time you read about it. Elevance Health (ELV) is the opposite case: its confidence score is built entirely on genuinely recent activity, and one person in particular has been buying, repeatedly, at progressively higher prices, for almost a year -- while the stock's institutional ownership base has been shrinking for two years straight.

The buying is fresh, not stale

ELV's score_30d and score_90d are identical: confidence 70, 3 buys, 2 unique buyers, no cluster alert, most recent buy dated July 17, 2026. As of this data's own timestamp (July 29, 2026), that's just 12 days old -- everything driving this score happened well within the last month, unlike a signal that's coasting on activity from months ago.

And it's not a one-off. President and CEO Gail Boudreaux bought ELV stock across three separate transactions on July 18, 2025 (2,334, 5,116, and 1,050 shares, between $286 and $288 per share), then came back and bought again on July 17, 2026 -- 680 shares at $366.41 and 2,045 shares at $368.25. That's a full year apart, and the second round of buying happened at a price roughly 28% higher than the first. A CEO who keeps adding to her own position as the price rises is a different pattern than someone buying once near a low and stopping.

She wasn't buying alone on July 17, either: director Ramiro G. Peru bought 1,000 shares that same day at $366.05 -- which is exactly why the confidence score counts 2 unique buyers over the last 30 days, not just one. Two other insiders bought earlier in the year: Executive Chairman Steven Collis purchased 3,000 shares at $289.84 in March 2026, and director Susan DeVore bought 1,200 shares at $312.15 back in August 2025. The handful of sells on file in the same broader window -- a few hundred to a few thousand shares each from Charles Kendrick (EVP & President, Commercial), Mark Kaye (CFO), Ronald Penczek (CAO), and Amy Schulman -- are smaller, scattered across different dates, and don't resemble one coordinated exit the way a founder's block sale might.

The institutional side tells a much rougher story

This is where ELV diverges sharply from both SPG and KKR. In the latest reporting period alone:

• Net institutional value change of -$11.0 billion.
• 606 net buyers vs. 859 net sellers -- a wider gap than KKR's, proportionally more lopsided toward selling.
• 121 new positions against 209 complete exits.
• Holder count fell from 1,564 (Dec 31, 2025) to 1,466 (Mar 31, 2026).

Zoom out further and the picture gets more dramatic: ELV's total disclosed institutional value peaked around $113.4 billion in mid-2024. As of the latest period, it's $57.7 billion -- a decline of roughly 49% over about two years. This isn't a single rough quarter; it's a sustained, multi-year institutional retreat, and the holder count has been trending down for several consecutive periods, not just this one.

A genuine divergence worth sitting with

Here's the tension: the person who arguably has the clearest internal view of Elevance Health's business -- its own CEO -- has bought more stock, at a meaningfully higher price than her prior purchase, within the last two weeks of this data being pulled. Meanwhile the institutional base has spent two years getting smaller, and the most recent quarter alone saw far more sellers than buyers.

We can't resolve which side is "right" from the filings alone, and this isn't a recommendation either way. What the data does support is that this is a genuinely more pointed divergence than a headline confidence score conveys -- it's not "insiders are buying," it's "the CEO specifically has bought twice, a year apart, at a rising price, against the grain of a shrinking institutional base." That's a much more specific thing to go investigate further (What's changed operationally? What do the specialist healthcare-focused conviction holders think?) than either side of the picture taken alone.

Who's still concentrated here

By dollar value, the largest holders are the familiar index giants: BlackRock ($5.82 billion), Vanguard Capital Management ($4.20 billion), State Street ($3.01 billion), Wellington Management Group ($2.41 billion), and Vanguard Portfolio Management ($1.86 billion).

By conviction, a set of well-known value-oriented investors surfaces instead: Brave Warrior Advisors at 8.13% of its disclosed portfolio, Baupost Group (a widely recognized value-investing manager) at 7.3%, and Ruane, Cunniff & Goldfarb (the firm behind the long-running Sequoia Fund) at 6.74%. Artisan Partners (2.41%) and Sanders Capital (2.06%) round out the top conviction holders. These are managers whose whole discipline is picking a small number of positions and holding them through volatility -- their continued concentration in a stock institutions broadly are fleeing is itself a data point worth weighing against the retreat.

Quick answers to common questions

Does the CEO buying at a higher price mean she expects the stock to keep rising? It's consistent with that view, but Form 4 doesn't disclose intent -- only that the purchase happened, at what price, and how large. Treat it as one input alongside everything else, not a stated forecast.

Is a shrinking institutional base always a bad sign? Not automatically -- it depends heavily on why. A sector-wide re-rating, a specific company issue, or simply funds rotating into other opportunities can all produce the same holder-count decline with very different implications. This article doesn't attempt to diagnose the cause; it's reporting what the ownership and insider data show.

Why mention Baupost and Sequoia's manager by name here? Because their long track records as concentrated, patient value investors are well-documented publicly, and a firm with that specific discipline choosing to stay meaningfully overweight a stock institutions broadly are exiting is a more informative data point than an anonymous "holder #47."

How to look this up yourself

• ELV's stock page has the full institutional holder list, ownership history going back over a decade, and insider activity in one place.
• Smart Money shows ELV's current standing next to every other ticker with an active convergence signal.
• Insider Trades lets you pull the same per-person, per-date Form 4 detail used above for any ticker.

The bottom line

ELV's insider-buying signal is unusual among the tickers we've profiled so far for being genuinely fresh rather than stale -- and for being anchored to one person, the CEO, buying twice across a year at a rising price. Set against an institutional base that's shrunk by roughly half over two years and saw far more sellers than buyers in the latest quarter alone, that's a real divergence worth digging into further, not a signal to read in isolation either way. Data as of July 29, 2026.